Compliance Rate
Compliance Rate
100.0%
Compliant submissions
2
Incompliant submissions
0
Total trials
2
My Organizations' Clinical Trials
Showing 475 of 910 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/30/13
End: 01/31/16
Due: 01/31/17
Phase: N/A
Priority: Normal
Start: 05/31/10
End: 08/31/15
Due: 08/31/16
Phase: N/A
Priority: Normal
Start: 02/28/13
End: 12/31/14
Due: 12/31/15
Phase: N/A
Priority: Normal
Start: 11/01/17
End: 06/01/20
Due: 06/01/21
Phase: N/A
Priority: Normal
Start: 09/30/10
End: 08/31/12
Due: 08/31/13
Phase: N/A
Priority: Normal
Start: 10/09/23
End: 04/01/27
Due: 04/01/28
Phase: N/A
Priority: Normal
Start: 10/04/21
End: 12/16/22
Due: 12/16/23
Phase: N/A
Priority: Normal
Start: 09/30/13
End: 10/31/14
Due: 10/31/15
Phase: N/A
Priority: Normal
Start: 01/31/09
End: 06/30/10
Due: 06/30/11
Phase: N/A
Priority: Normal
Start: 05/19/17
End: 11/08/18
Due: 11/08/19
Phase: N/A
Priority: Normal
Start: 12/05/23
End: 02/08/24
Due: 02/08/25
Phase: N/A
Priority: Normal
Start: 09/15/17
End: 06/01/19
Due: 06/01/20
Phase: N/A
Priority: Normal
Start: 07/31/15
End: 05/31/17
Due: 05/31/18
Phase: N/A
Priority: Normal
Start: 01/31/10
End: 07/31/19
Due: 07/31/20
Phase: N/A
Priority: Normal
Start: 04/30/09
End: 12/31/12
Due: 12/31/13
Phase: N/A
Priority: Normal
Start: 10/01/22
End: 12/10/24
Due: 12/10/25
Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated Venothromboembolism
Phase: N/A
Priority: Normal
Start: 08/31/06
End: 01/31/12
Due: 01/31/13
Phase: N/A
Priority: Normal
Start: 05/31/08
End: 06/30/13
Due: 06/30/14
Phase: N/A
Priority: Normal
Start: 09/01/16
End: 03/17/20
Due: 03/17/21
Phase: N/A
Priority: Normal
Start: 03/15/23
End: 04/30/25
Due: 04/30/26
Phase: N/A
Priority: Normal
Start: 05/15/25
End: 03/31/28
Due: 03/31/29
Phase: N/A
Priority: Normal
Start: 08/23/20
End: 12/04/24
Due: 12/04/25
Phase: N/A
Priority: Normal
Start: 01/31/12
End: 12/31/27
Due: 12/31/28
Phase: N/A
Priority: Normal
Start: 12/16/20
End: 09/20/24
Due: 09/20/25
Phase: N/A
Priority: Normal
Start: 07/25/19
End: 03/19/21
Due: 03/19/22